Alzheimer's disease (AD) is characterized by progressive decline in cognition, memory and intellect. It has been hypothesized that amyloid-β peptide (A-β) may have a prominent role in neurodegeneration. Oxidative mechanisms have been implicated in this pathway. There is substantial evidence that inflammatory mechanisms, induced by tumour necrosis factor α (TNF-α), are also involved in AD. TNF-α activates receptors linked to multiple effector systems, including a sphingomyelin pathway and peroxide oxidation. We have determined the changes of neutral sphingomyelinase activity, sphingomyelin and ceramide contents, and the level of lipid peroxide products (conjugated dienes), in the cerebral cortex, hippocampus and cerebellum of rats within 3 h and 7 days of intracerebral injection of A-β and TNF-α. A single injection of A-β and TNF-α has been shown to increase the level of peroxide products in the hippocampus and cerebral cortex within 3 h and 7 days. Sphingomyelinase activity and ceramide levels have been found to increase 7 days after A-β administration. We found that activation of the sphingomyelin pathway lies downstream from the oxidative stress.
Introduction
Alzheimer's disease (AD) is the most common form of dementia, affecting more than 10% of the population over the age of 65 years. The disease is characterized by a progressive degeneration of neurons in certain brain areas and by a decline in cognition, memory and intellect. It has been suggested that neuronal loss is the result of amyloid β-peptide (A-β) neurotoxicity [1] . A-β is the main constituent of senile plaques found in the brain of AD patients [2] . The A-β cascade hypothesis postulates the generation of free radicals [3] and, thereby, oxidative disorders in cellular constituents [4] . There is substantial evidence that inflammatory mechanisms, induced by tumour necrosis factor α (TNF-α) and other cytokines, are also involved in AD [5] . TNF-α activates receptors linked to multiple effector systems, including peroxide oxidation. The involvement of free radicals in the pathogenesis of AD is accepted for the following reasons: (i) brain metabolism requires substantial quantities of oxygen; (ii) neurons are particularly sensitive to free radical attack, because their glutathione content is very low, but their membranes contain a high proportion of polyunsaturated fatty acids; (iii) A-β is sensitive to the action of free radicals, contributing to its aggregation; (iv) traces of metals (Fe, Cu, Zn and Al) that are capable of catalysing reactions that produce free radicals have been found in the brain of AD patients; (v) AD is related to mitochondrial anomalies, particularly in cytochrome c oxidase, and these Key words: Alzheimer's disease, amyloid-β peptide, ceramide, lipid peroxidation, tumour necrosis factor α (TNF-α), sphingomyelin cycle. Abbreviations used: A-β, amyloid β-peptide; AD, Alzheimer's disease; SPM, sphingomyelin; SPMase, sphingomyelinase; TNF-α, tumour necrosis factor α. 1 To whom correspondence should be addressed (e-mail ales@sky.chph.ras.ru).
anomalies may explain the abnormal production of free redicals; (vi) aging is the principal AD risk factor and is itself related to accumulated free radical attacks; (vii) free radical scavengers reduce the toxicity of A-β; and (vii) the clinical use of many free radical scavengers (vitamin E, drugs from Ginkgo biloba extract, oestrogen) and iron-chelating agents is quite successful.
This evidence clearly supports the involvement of free radicals and reactive oxygen species in AD. However, it is unknown whether free radicals are really one of the basic causes of the pathogenesis and neuronal damage in AD.
It is well known that neuronal death occurs according to an apoptotic programme [6] . Most signalling pathways that trigger apoptosis remain unknown, but the sphingomyelin (SPM) pathway has been recognized as a ubiquitous signalling system that links specific cell-surface receptors and environmental stresses to the nucleus [7] . This pathway is initiated by the hydrolysis of SPM via the action of sphingomyelinases (SPMases) to generate ceramide. Ceramide then serves as a second messenger in this system, leading to apoptosis.
Taking together the role of free radical reactions in the pathogenesis of AD and the participation of the SPM pathway in apoptosis of neuronal cells, we have monitored induction of the SPM cycle and activation of lipid peroxidation in rat brain sections after single intracerebral injections of A-β-(25-35) and TNF-α, and a combination of both.
Methods
Young adult male Wistar rats (230-280 g) were used in our experiment in accordance with the European Communities Council Directive (86/609/EEC) for the care and use of animals for experimental procedures. Surgical procedures were performed under chloral hydrate anaesthesia.
Aggregated A-β and TNF-α were injected intracerebrally into rats in doses of 3 nmol and 1 µg per rat respectively.
In the neutral SPMase assay, fresh brain sections (cortex, hippocampus and cerebellum) were washed with Hanks buffer and then homogenized in neutral SPMase assay buffer. The activity of the enzyme was measured according to the method of Hostetler and Yazaki [8] .
SPM and ceramides were separated by TLC. Lipid peroxide oxidation intensities were measured spectrophotometrically as the content of conjugated dienes and ketodienes in lipid extracts, at 233 nm and 270 nm respectively.
All values are presented as means ± S.E.M. Statistical comparisons were performed by Student's t test. Significance was set at a value of P < 0.05.
Results and discussion
Reactive oxygen metabolites have been implicated in the pathogenesis of many forms of brain disease, including AD. Although much has been published concerning lipid peroxidation, the specific role of this process in brain-cell death remains unclear. Recently, it was shown that superoxide radicals are used as signalling molecules within the SPM pathway [9] . This means that there is cross-talk between the oxidation system and the SPM cycle in cells, which could have important implications for the induction phase and evolution of AD.
We have determined the changes in neutral SPMase, SPM and ceramide contents and level of lipid peroxide products (conjugated dienes and ketodienes) in the cerebral cortex, hippocampus and cerebellum of rats within 3 h and 7 days of intracerebral injection of A-β and/or TNF-α. Maximal changes in SPMase activity, and SPM ceramide contents after single TNF-α and A-β administration were found in the hippocampus, and were less expressed than in the cerebral cortex and cerebellum. We found increased lipid peroxidation 3 h after injection of peptides into the rat brain, but the activity of SPMase did not increase. Remarkable increases in SPMase activity and ceramide content were found 7 days after injection of A-β ( Figures 1A and 1B) .
In our studies, we found a link between activation of SPMase and accumulation of ceramide 7 days after injection of A-β. A wide variety of extracellular stimuli, such as TNF-α, interleukin 1β, nerve growth factor, chemotherapeutic agents and serum deprivation, activate hydrolysis of SPM, resulting in ceramide release. Ceramide then serves as a 'second messenger' in the induction of apoptosis.
Increases in the levels of peroxide products in the hippocampus 7 days after injection of A-β and TNF-α were still remarkable (Figures 2A and 2B ), but combined injection of TNF-α and A-β in the rat brain decreased the activity of SPMase and level of ketodienes to normal after 7 days (Figures 1 and 2) . It was proposed that TNF-α may protect brain cells from injury induced by A-β. The role of TNF-α in the pathogenesis of AD is unclear because it has been shown to be involved in both neuroprotection and neurodegeneration, depending on doses and age of animals [9] . Small doses of TNF-α induced a protective effect against A-β neurotoxicity [10] . In our experiments we used low doses of TNF-α.
We suggest that using low doses of TNF-α for clinical prevention of AD development might be possible. We also propose that new drugs that protect brain cells from SPM digestion could be used for preventing or slowing the onset of AD.
